Evotec SE (EVO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.52 (-0.65% 1D, market cap $544.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, EVO ranks #307 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and PBYI (Puma Biotechnology Inc) posts a B- grade (70/100 RQD, P/E 17.5x, ROIC 29.3%, cap $538.9M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #307 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.2M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While EVO currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.63) and Max Pain ($1.60) forces dealer call-delta covering toward $4.29.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Evotec SE (EVO) slipped -0.65% to $1.52, trading at 7% of its 52-week range ($1.33 – $4.09). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Investing News Network report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026
Evotec’s latest announcement landed hard. Management cut its 2026 revenue and EBITDA guidance after partnership milestones slipped, then reported weaker Q2 2026 figures with a deeper net loss. For Evotec shareholders, th
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EVO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EVO. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Evotec SE (EVO) ranks #307 by composite RQD confidence (47/100, grade D) and #426 by equity capitalization ($544.3M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with EVO at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EVO
ACTIVE
Evotec SE | D | 47/100 | — | — | — | -0.65% | $544.3M | Benchmark Subject |
| DRUG Bright Minds Biosciences Inc. | D | 46/100 | — | — | — | -52.35% | $539.9M | /drug-vs-evo → |
| PBYI Puma Biotechnology Inc | B- | 70/100 | 17.5x | 74.5% | 29.3% | -2.49% | $538.9M | /pbyi-vs-evo → |
| NGNE Neurogene Inc. | D- | 36/100 | — | — | -35.0% | -3.41% | $551.3M | /ngne-vs-evo → |
| STTK Shattuck Labs Inc. | E | 29/100 | — | — | -35.0% | -4.32% | $558.0M | /sttk-vs-evo → |
Evotec SE (EVO) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $544.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.52 (-0.65% 1D, market cap $544.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, EVO ranks #307 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and PBYI (Puma Biotechnology Inc) posts a B- grade (70/100 RQD, P/E 17.5x, ROIC 29.3%, cap $538.9M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #307 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
EVO last traded at $1.52 (-0.65% on volume of 67,643 shares), positioning the stock -6.75% below its 50-day simple moving average ($1.63) and -39.20% below its 200-day simple moving average ($2.50). Across its 52-week range of $1.33 to $4.09, EVO sits at the 6.9% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($1.42 to $1.62).
Evotec SE (EVO) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.52 (-0.65% 1D, market capitalization $544.3M).
Evotec SE (EVO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.6B.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), EVO carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Evotec SE (EVO) • Click "Debate This Headline" to argue it in the Roar Pit below
Investing News Network report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.
Long EVO at $1.53 targeting $2.02. The forensic balance sheet pillar scores 13 of 20 with an Altman Z of 2.5 and a Piotroski F of 6/9, the strongest component of the rating.. Institutional whale score is 5/20 and the risk/reward vs. the $1.33 52-week low is skewed heavily in favor of bulls.
@ForensicBear Shorting a 5/20 institutional whale-flow stock at $1.53 is dangerous when funds are rotating into Health Care.
Sitting on the sidelines or leaning short EVO above $1.53. ROIC and FCF yield are both 0% and the stock trades at $1.58, near the lower end of its $1.33 - $4.09 52-week range, with an RQD grade of D.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $4.09.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).